Joseph Ashley
Mark Levine
Florence H Sheehan, M.D.
Ed Garth
Scott Ashley
Mary Waiss
Board of Directors
Scientific Advisory Board
Joseph Ashley - Founder, Chairman, President and Chief Executive Officer
- President, Clinical Instrument Division, Beckman Instruments, Inc. During Mr. Ashley's tenure corporate sales grew over a nine year period from US$10 million to US$450 million worldwide. In 1982 Beckman Instruments, Inc. merged with SmithKline Corporation, creating SmithKline Beckman Corporation.
- Chairman of the board ICOM, a Chicago based software development company. In 1988 ICOM was sold to Viacom.
- President, Genetic Systems, an early bio-tech startup. The company was sold to Bristol-Meyer in 1985 for $300million.
- CEO, Biomed, a biotech company which developed vaccines for the fish farming industry. The company was eventually sold to a Swedish pharmaceutical manufacturer.
- Founder and CEO, ProCyte Corporation, a pharmaceutical development company. ProCyte completed its initial public offering on the NASDAQ in 1989, and was subsequently acquired by PhotoMedex, Inc. in 2004.
- Chairman of the board, Design Intelligence, a Seattle based software company, which was sold to Microsoft in 2000.
- Chairman of the board, Copernicus Therapeutics Inc., a biotechnology company in genetic pharmaceuticals.
- Founder and director of Sound Pharmaceuticals, an early stage company working on means of protecting against loss of hearing.
top
Mark Levine - Vice President, Sales and Marketing
- President of York Instrument Corp, manufacturer of precision liquid handling equipment for use in hospital and research laboratories. Marketing Manager at Manostat Corp, a chemistry laboratory equipment supplier, and
- District Marketing Manager with Research Specialties Co, a manufacturer of automated chemistry analyzers and gas/liquid chromatographs.
- Program/business manager, Clinical Instruments Division, Beckman Instruments.
- Managed business teams of marketing, manufacturing, development and finance personnel in the identification of specific product opportunities, and the subsequent definition of the product that would meet that need.
- Led project teams through the development, manufacturing and marketing phases of various projects; ranging from small manual instruments to fully automated systems, one of which generated over $1 billion in revenue over the products life cycle.
top
Florence H. Sheehan, M.D. - Founder, Chief Scientist
- Professor of Medicine/Cardiology at the University of Washington.
- Twenty-seven years experience in cardiac image analysis.
- Developed the centerline method for measuring regional ventricular function.
- Directed the development of the CenterLine wall motion method. This method carries an FDA 510(k) and has been licensed to 15 companies, bringing in $1,466,326 to date.
- Holds 7 patents in the field of quantitative cardiac imaging.
- Director of the Cardiovascular Research and Training Center at the UW, which has served as the Core Laboratory for image analysis to over a dozen multi-center clinical trials.
top
Ed Garth - Vice President, CFO
- Twenty-five years of operating expertise in building and financing emerging technology related companies.
- CFO and SVP of Administration of Coscomm International Inc., an early stage company developing a satellite based mobile communication solution for the public safety market.
- Mr. Garth was integral in orchestrating the financing, positioning and sale of substantially all of Design Intelligence Inc.’s (DI) business and assets to Microsoft. Mr. Garth was a Co-founder of DI and served as its Vice President of Finance and Administration during the periods of development and sales prior to the Microsoft sale and then as its President during the subsequent two year transitional period to complete the sale.
- Mr. Garth held executive officer positions at Virtual Vision, Inc. (heads up display developer and manufacturer) and Mac’s Place, Inc (catalog software/hardware reseller).
- As President and sole proprietor of The Financial Solutions Company, he served as an interim executive officer for many high technology and biotechnology companies, with operations that included and evolved from pure startups to publicly traded operating companies.
- Throughout his career, Mr. Garth has been on the receiving end of well in excess of 100 financings, including; private offerings, venture capital offerings, public offerings, licensing agreements, corporate partnering, corporate sale, bank financings and asset based financings.
- Prior to his operating experience with emerging companies, Mr. Garth began his career as a tax consultant supervisor and auditor with Deloitte & Touche.
top
Scott Ashley - Vice President, Research and Development
- Twenty-six years of core operating system software development, project management, first-line, second-line, and director experience.
- Director of software development for HP Integrity NonStop NS16000 Server. Managed a team of over 80 software developers; operating systems, low-level millicode, compilers, debuggers, QA groups. Either directly controlled or influenced an annual division-wide budget of more than $10M.
- Key driving force across the Tandem NonStop Division introducing quality improvement activities that reduced defect introduction rates and increased schedule accuracy.
- Second line management responsibility for Tandem NonStop device driver development group, managing a team of 35 software developers; device driver, device diagnostics, device software quality assurance groups. Responsible for the device driver level changes across those groups for the support of the Tandem NonStop S7000 and S70000 products.
- Manager Tandem device driver group. Responsible for rebuilding a software development group from 1 person to 8 people. Managed all software development activities supporting disk, tape, optical disk and generic SCSI devices. Drove major quality improvement project to re-write the key Tandem NonStop device driver software.
top
Mary Waiss - Vice President, Clinical Development
- Twenty-five years experience in all aspects of cardiac ultrasound; including clinical, research, industry and education with emphasis on physics and instrumentation, adult and pediatric cardiology and congenital heart disease.
- Research scientist, Cardiovascular Research Lab and Training Center, University of Washington; Led and supported a variety of research projects related to 3-D image acquisition, analysis and remote guidance.
- Doppler physics/Echocardiography educator- ATL, Bothell, WA; Hewlett-Packard, Andover, MA; Bellevue Community College, Bellevue, WA
- Chief echocardiographer- Children’s Hospital, Boston, MA;
- RDCS – pediatric and adult echocardiography
top
Board of Directors
Joseph Ashley - Founder, Chairman, President and Chief Executive Officer
See above for Mr. Ashley's bio.
top
Treuman Katz - Member of Audit Committee, Member of Compensation, Governance and Nominating Committee.
Mr. Katz is currently the President Emeritus of the Seattle Children's Hospital & Regional Medical Center ("Seattle Children's"), after serving as its President and Chief Executive Officer from 1979 to October 2005. Under his leadership, Seattle Children's became one of America's top five children's hospitals with assets of over US$1 billion and an annual budget of more than US$500 million. Mr. Katz led the strategic planning process that resulted in the creation and establishment of the Seattle Cancer Care Alliance; Children's University Medical Group (CUMG), a major joint venture between Children's Health Care System and the University of Washington School of Medicine; Child Health Corporation of America, a national venture of 42 hospital organizations; Airlift Northwest, a consortium organized to transport patients throughout the Northwest by fixed-wing and helicopter; and a multi-organ transplant program established at Seattle Children's for heart, liver, small bowel, and bone marrow. Prior to his tenure at Seattle Children's, Mr. Katz served as a senior executive at Cedars-Sinai Medical Center in Los Angeles. Mr. Katz has a Masters degree in Science from the University of California at Berkeley, California and an MBA from George Washington University in Washington D.C.
top
Danny Dalla-Longa – Director, Chairman of the Compensation, Governance and Nominating Committee, Member of Audit Committee. (Former CEO and Chairman of Luca Capital Inc.)
Mr. Dalla-Longa holds a Bachelor of Commerce from the University of Calgary, Chartered Business Valuation degree, as well a two valuation degrees from the U.C and also is a Chartered Accountant. During the years of 1993 to 1997, Mr. Dalla-Longa served as an MLA as the energy critic in the Alberta Legislature. Prior thereto he was a partner ... in corporate and business valuations for 18 years with the international accounting firm, KPMG. Mr Dalla-Longa has had extensive experience with public companies in a number of different industry sectors.
top
Dr. Eldon Smith – Director, member of Compensation, Governance and Nominating Committee.
1980 became professor and founding Head of the Division of Cardiology at the University of Calgary and Foothills Hospital. He was named Head of the Department of Medicine in 1985 was Dean of the Faculty of Medicine (1992-97). He retired from medical practice in 2003 and became Professor Emeritus at the University of Calgary the following year. Currently he is Editor-in-chief of the Canadian Journal of Cardiology. Dr. Smith was awarded the 2005 Canadian Medical Association (CMA) Medal of Service in recognition of his outstanding contributions in many facets of medicine as a clinician, researcher, educator, administrator and ambassador.
top
Dr. Udo Heneseler, CPA – Chair of Audit Committee, Member of Compensation, Governance and Nominating Committee.
Currently the principal/owner of MSI Management Services International (a privately owned business initiated in 1994). MSI provides services related to contract CEO, CFO and business development engagements for emerging biotechnology firms in domestic and international settings. From 2002 to July 2005, Dr. Henseler was the CEO and Chairman and until February 2006 a Director of eGene, Inc., a publicly traded biotechnology company in the genotyping market. From 1999 to June 2002, Dr. Henseler was a director and from June 2001 to March 2002, he was the Executive Vice President and CFO of ChemoKine Therapeutics Corporation, a biopharmaceutical company with products for use in patients with cancer and multiple sclerosis. From 2000 to June 2001, he was Senior Vice President and CFO of Isotag Technology, Inc., a biotechnology identification products and services company. Dr. henseler brings over 40 years of executive management with extensive public company experience in the life sciences industry, including past and present board and committee memberships.
top
Scientific Advisory Board
- Thomas K. Jones, M.D., Scientific Advisory Board Chair - Professor of Pediatrics and Director of the Cardiac Catheterization Laboratories at Seattle Children’s Hospital and Regional Medical Center. A pediatric heart expert, Dr. Jones is internationally recognized and is a pioneer in developing new heart treatments.
- Michael Gatzoulis, M.D., Ph.D., F.A.C.C., Consultant Cardiologist in Cardiology and Pediatrics at the Royal Brompton Hospital, London.
- Mark Lewin, M.D., Associate Professor of Pediatrics and co-Director of the Echocardiography Laboratory at Seattle Children's Hospital and Regional Medical Center.
- David Sahn, M.D., Professor of Pediatrics at Oregon Health & Science University (OHSU) in Portland, Oregon.
top
|
